AYALA PHARMACEUTICALS, INC.
Profile
Company Names
AYALA PHARMACEUTICALS, INC.
ADVAXIS, INC.
Addresses
9 DEER PARK DRIVE, SUITE K-1, MONMOUTH JUNCTION, NJ 08852
9 DEER PARK DRIVE, SUITE K-1, MONMOUTH JUNCTION, NJ 08852
305 COLLEGE ROAD EAST, PRINCETON, NJ 08540
TECHNOLOGY CENTRE OF NEW JERSEY, 675 ROUTE 1, NORTH BRUNSWICK, NJ 08902
Phone Numbers
732 545 1590
732-545-1590
609-452-9813
Entity Type:
CORPORATION
Industry:
BIOTECHNOLOGY
Year Incorporated:
> 5 years ago
State Incorporated:
DELAWARE
Total Amount Raised:
$44,853,919.00
Number of Funding Rounds:
14
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
14
2023-10-18
$433,825.00
$433,825.00
$0.00
Equity
13
2022-01-31
$4,750,000.00
$4,750,000.00
$0.00
Equity
12
2021-04-14
$11,093,521.00
$11,093,521.00
$0.00
11
2012-11-13
$0.00
$10,000,000.00
$10,000,000.00
Equity
10
2012-05-18
$715,000.00
INDEFINITE
INDEFINITE
Debt
9
2012-05-14
$4,473,673.00
INDEFINITE
INDEFINITE
Equity
8
2012-01-09
$1,047,500.00
INDEFINITE
INDEFINITE
Debt
7
2011-10-31
$1,977,500.00
INDEFINITE
INDEFINITE
Debt
6
2011-05-12
$6,016,250.00
INDEFINITE
INDEFINITE
Debt
5
2010-11-01
$835,000.00
INDEFINITE
INDEFINITE
Debt
4
2010-07-19
$7,500,000.00
$7,500,000.00
$0.00
Equity
3
2009-10-07
$50,000.00
INDEFINITE
INDEFINITE
Debt
2
2009-09-24
$5,000,000.00
$5,000,000.00
$0.00
1
2009-06-17
$961,650.00
INDEFINITE
INDEFINITE
Debt
People
First Name
Middle Name
Last Name
Titles
Related Companies
RICHARD
BERMAN
DIRECTOR
VERED
BISKER-LEIB
DIRECTOR
ANDRES
GUTIERREZ
EXECUTIVE OFFICER
BRIDGET
MARTELL
DIRECTOR
THOMAS
MOORE
DIRECTOR, EXECUTIVE OFFICER
PINI
ORBACH
DIRECTOR
MARK
J.
ROSENBLUM
EXECUTIVE OFFICER
DAVID
SIDRANSKY
DIRECTOR
ALFACELL CORP
| KV PHARMACEUTICAL CO /DE/
| ROSETTA GENOMICS LTD.
| MORRIA BIOPHARMACEUTICALS PLC
| CHAMPIONS ONCOLOGY, INC.
| CELSUS THERAPEUTICS PLC.
| Y LABS, INC.
| IMMUNE PHARMACEUTICALS INC
| ORGENESIS INC.
| TAMIR BIOTECHNOLOGY, INC.
| GALMED PHARMACEUTICALS LTD.
| ISRAEL BIOTECH FUND II, L.P.
| ADVAXIS, INC.
| AYALA PHARMACEUTICALS, INC.
ROBERT
SPIEGEL
DIRECTOR
FACE2FACE PARTNERS I, LLC
| PRE-IPO OPPORTUNITIES FUND LLC
| EDGE THERAPEUTICS, INC.
| NEXIMMUNE, INC.
| ACUITY OPPORTUNITIES FUND I LLC
| PINES AT WOODCREEK INVESTOR LLC
| ACUITY DATAMINR LLC
| ACUITY DATASTAX LLC
| ACUITY VARO BANK LLC
| ACUITY TANIUM LLC
| ACUITY TURO LLC
| ACUITY EPIRUS LLC
| ACUITY SPV VII LLC
| AYALA PHARMACEUTICALS, INC.
| RENOVORX, INC.
| CYCLACEL PHARMACEUTICALS, INC.
| DAWSON FOREST INVESTORS LLC
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2023-10-18
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
$1,000,001 - $5,000,000
Equity
2022-01-31
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
$1,000,001 - $5,000,000
2021-04-14
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2012-11-13
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Debt
2012-05-18
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2012-05-14
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Debt
2012-01-09
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Debt
2011-10-31
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Debt
2011-05-12
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Debt
2010-11-01
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2010-07-19
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Debt
2009-10-07
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Debt
2009-06-17
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
EVAN GREENBERG
NONE
NONE
NONE
EVAN GREENBERG
NONE

